SCHEMBL7613745

SCHEMBL7613745

CN1CCC=C(c2nsnc2SCCCCSC2=NCCS2)C1

nearest known ligand 0.79

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 11/20 0.79
CHRM4 P08173 3/20 0.77
SIGMAR1 Q99720 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7613172 0.99 CHRM1 (0.79) CHRM1CHRM4SIGMAR1
Oxalic Acid SCHEMBL7620928 0.94 CHRM1 (0.70) CHRM1CHRM4
Oxalic Acid SCHEMBL7616433 0.93 CHRM1 (0.70) CHRM1CHRM4
SCHEMBL8196563 0.89 CHRM1 (1.00) CHRM1CHRM4SIGMAR1
SCHEMBL8189336 0.88 CHRM1 (1.00) CHRM1CHRM4SIGMAR1
SCHEMBL8189299 0.88 CHRM1 (1.00) CHRM1CHRM4SIGMAR1
SCHEMBL8196549 0.86 CHRM1 (1.00) CHRM1CHRM4SIGMAR1
SCHEMBL8712229 0.85 CHRM1 (0.69) CHRM1CHRM4SIGMAR1
SCHEMBL6912246 0.84 CHRM1 (0.90) CHRM1CHRM4
SCHEMBL7616440 0.83 CHRM1 (0.61) CHRM1CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0734259-B1 Use of piperidine compounds in the treatment of schizophrenia NOVO NORDISK AS (DK) 2002-06-12 EP claimed
US-RE36375-E Treatment of Alzheimer's disease using azacyclic compounds NOVO NORDISK A/S (DK) 1999-11-02 US claimed
US-RE35822-E COGNITION ACTIVATORS NOVO NORDISK A/S (DK) 1998-06-09 US claimed
US-5658932-A AZACYCLIC COMPOUNDS; COGNITIVE FUNCTION STIMULANTS; ALZHEIMER'S DISEASE NOVO NORDISK A/S (DK) 1997-08-19 US claimed
US-5571826-A 1,2,5-THIADIAZOLE OR 1,2,5-OXADIAZOLE AS ANALGESICS NOVO NORDISK A/S (DK) 1996-11-05 US claimed
EP-0734259-A1 ANTIPSYCHOTIC METHOD NOVO NORDISK A/S (DK) 1996-10-02 EP claimed
EP-0732925-A1 A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS NOVO NORDISK A/S (DK) 1996-09-25 EP claimed
US-5545638-A USING A 3-(TETRAHYDROPYRID-3-YL-) SUBSTITUTED (OXA- OR THIA-)DIAZOLE COMPOUND NOVO NORDISK A/S (DK) 1996-08-13 US claimed
EP-0687265-A1 HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1995-12-20 EP claimed
WO-1995017185-A1 A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS NOVO NORDISK A/S (DK) 1995-06-29 WO claimed
WO-1995005174-A1 ANTIPSYCHOTIC METHOD NOVO NORDISK A/S (DK) 1995-02-23 WO claimed
US-5376668-A Cholinergic agents as cognition activators in treatment of Alzheimer*s disease NOVO NORDISK A/S (DK) 1994-12-27 US claimed
WO-1994020495-A1 HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1994-09-15 WO claimed
EP-0709094-B1 Tetrahydropyridine oxadiazole or thiadiazole compound for treating anxiety LILLY CO ELI (US) 2000-04-05 EP disclosed
US-5708014-A SUBSTITUTED TETRAHYDROPYRIDINYL-1,2,5-OXADIAZOLES OR THIADIAZOLES ELI LILLY AND COMPANY (US) 1998-01-13 US disclosed
EP-0709094-A2 Method for treating anxiety using a tetrahydropyridine oxadiazole or thiadiazole compound ELI LILLY AND COMPANY (US) 1996-05-01 EP disclosed